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ABSTRACT Constraints of a multireplicon chromosomal or-
ganization and of the necessity to maintain constant gene dosages
demand that each origin of replication in a eukaryotic cell "fire"
(initiate replication) only once per cell cycle. The central idea of
this work is that a low probability ofan extra ("illegitimate") round
ofDNA replication (called below "replicon misfiring") within any
given chromosomal domain could be increased by certain sub-
stances of either intra- or extracellular origin. The term "firone"
is proposed for such a substance. It is shown that existence of fir-
ones could greatly speed up evolution of cellular systems under
selection pressure, a developing tumor being one example of such
a system. Experimentally testable predictions of the firone hy-
pothesis are discussed.
One feature ofeukaryotic DNA replication is tight control ofthe
number of initiation events per origin ofreplication. Apart from
a few special cases (2-5), each origin of replication in a eukar-
yotic cell fires only once per cell cycle; repetitive firings at the
same origin are prevented, apparently by a special mechanism
(6-8). Reasons for the tight control of the frequency of repli-
cation initiation include constraints imposed by a multireplicon
chromosomal organization, by complex mitotic mechanisms,
and by the necessity to maintain constant gene dosages for at
least some ofthe genes. Molecular mechanisms for suppression
of extra rounds of DNA replication are unknown and may in-
clude specific chromatin structures at the replication origins or
termini and possibly replication-dependent chemical modifi-
cations of DNA segments involved in replication initiation.
The important point, however, is that the probability of an
extra ("illegitimate") round of DNA replication (called below
"replicon misfiring") within any given chromosomal domain,
although generally very low, is not zero, as indicated by the
following lines of evidence.
Multiple rounds ofDNA replication at certain chromosomal
loci in the polytene chromosomes of an insect Rynchosciara
result in so-called DNA puffs (4). This is an example of a de-
velopmentally controlled repeated firing of a specific replicon.
Other examples are the phenomenon of ribosomal DNA am-
plification in many different species (3) and the recently dis-
covered amplification of genes for chorion proteins during oo-
genesis in Drosophila (5). Recent work by Botchan et al. (2)
indicates that locus-specific replicon misfiring is responsible
also for production of free circular simian virus 40 (SV40) DNA
molecules after fusion of permissive green monkey cells with
nonpermissive SV40-transformed mouse cells. The replication
origin of integrated SV40 DNA does not function more than
once per cell cycle (2, 9). However, upon fusion of a nonper-
missive SV40-transformed mouse cell with a permissive monkey
cell, a burst of SV40 replicon misfiring produces extrachro-
mosomal copies of SV40 DNA (2).
That the phenomenon of replicon misfiring is not limited to
locus-specific events and highly special cases is indicated by the
following lines of evidence.
Cultured mammalian (10) and insect (Drosophila) cells (11)
contain small but detectable amounts of their nuclear DNA se-
quences in the form of circular DNA molecules ranging in size
from less than one to several kilobase pairs (kbp) and enriched
in dispersed, middle repetitive DNA sequences (11). Although
the available evidence (10, 11) is compatible with several dif-
ferent interpretations, one explanation is that small circular
DNAs may be the result of infrequent events of replicon mis-
firing occurring preferentially within chromosomal regions con-
taining stretches of dispersed repetitive DNA. In some cases
the latter have been shown to behave as transposable elements
(12).
In several cases of drug resistance, the cellular phenotype
is known to be due to an overproduction of an enzyme that is
the specific target of the drug in question (1, 13-21). For ex-
ample, an overproduction of dihydrofolate reductase (DHFR;
EC 1.5.1.3) in mouse cells resistant to the specific DHFR in-
hibitor methotrexate (MTX) was shown to be due to an increase
in the number of DHFR genes per cell (13, 22). The extra
DHFR genes are found either in small acentric chromosomes
[double minute chromosomes (DMs) (23)] or integrated within
specific regions of certain mouse chromosomes (24, 25). The
extra copies of the DHFR gene accumulating in the course of
selection for resistance to increasing concentrations ofMTX are
most likely the result ofinfrequent misfirings ofthe DHFR rep-
licon, each misfiring producing an extra copy of the functional
DHFR gene and its chromosomal domain. The increase in the
DHFR gene dosage leads to an increase in the amount ofDHFR
and thus improves the cell's chances for survival in the presence
of an otherwise lethal concentration of MTX (13). Incidence of
mouse cells resistant to a low MTX concentration (-=100 nM)
is ofthe order of106 (13), suggesting that the probability ofthe
DHFR replicon misfiring within a single cell cycle is at least
10-6.
Another example of a similar kind is the amplification of the
CAD [CAD is the multifunctional protein containing the en-
zymatic activities carbamoyl-phosphate synthetase (EC 6.3.5.5),
aspartate carbamoyltransferase (EC 2.1.3.2) (aspartate trans-
Abbreviations: DHFR, dihydrofolate reductase; CAD, the multifunc-
tional protein containing the enzymatic activities carbamoyl-phosphate
synthetase, aspartate carbamoyltransferase (aspartate transcarbamoyl-
ase), and dihydro-orotase (1); DMs, double minute chromosomes (small
acentric chromosomes); MTX, methotrexate; kbp, kilobase pair(s); TPA,
12-O-tetradecanoylphorbol 13-acetate; SV40, simian virus 40.
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FIG. 1. Firone hypothesis. (A) Definition of replicon misfiring. I. A chromosomal region containing three origins of replication (o) is shown. II.
Misfiring event in GI phase of the cell cycle is depicted as a single replication bubble growing from the middle origin. This event is classified as
a misfiring because, by definition, no chromosomal origin of replication should be active in G1 phase. Arrows denote directions of fork movement.
m. Misfiring event in the S phase is depicted as an extra replication bubble growing within one of the two branches of an active middle replicon.
Subsequent excision of an extra copy of a chromosomal domain produced may be carried out either by a general recombinational enzymatic system
or by a special repair-type mechanism (1). IV. Misfiring event in the G2 phase is analogous to that in the S phase except that a "legitimate" DNA
replication is depicted finished, with replication forks meeting each other at points ofsubsequent DNA segregation. One additional assumption used
to produce IV is that DNA segregation is a G2-specific event; that is, no DNA segregation takes place in S phase, at least in a chromosomal region
shown. It is not known whether the probability of a misfiring for any replicon differs strongly among G1, G2, and S periods of the cell cycle. Firones
are postulated to increase the frequency ofreplicon misfiring either at specific chromosomal locations (locus-specific firones) or all over the genome
(locus-unspecific firones).
(B) Possible role of replicon misfiring in facilitating an increase in dosage of a "transforming" gene. This diagram shows a pair of homologous
chromosomes carrying a dominant normal allele (t) and a mutated recessive allele (t') which is transforming. Before the first cell division, random
replicon misfiring leads to a formation of an extra copy of t', the copy being released as an acentric DM or as a smaller chromatin fragment (black
square). At this stage, the greater-than-normal ratio of t' to t (2:1) is presumed to be insufficiently high to overcome a dominant effect ofthe normal
allele t. After the second cell division, however, one of the two daughter cells randomly acquires both extra copies of the transforming t' allele and
the increased ratio of t' to t (3:1) is assumed to be sufficiently high to cause phenotypic alteration, denoted as initial transformed phenotype. Note
that, unlike the first extrachromosomal copy of t', the second extra t' copy was formed not by a replicon misfiring but by a conventional, cell cycle-
dependent replication of the first extra t' copy (black squares). Other cells of the same lineage are shown to acquire extrachromosomal copies of
the normal allele t (white squares) randomly, with no alteration in phenotype.
(C) Cellular gene dosage assay for firone detection. Incidence of MTX-resistant, colony-forming cells is determined for a range ofMTX concen-
trations by seeding known amounts of cultured mammalian cells in the presence of different concentrations ofMTX and determining the numbers
of resistant cells. This can be done by scoring the colonies that MTX-resistant cells give rise to. The resulting dose-response curve (solid line) is
then compared with an experimental curve (dashed line) derived from cells grown for several generations in the presence of a putative firone before
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carbamoylase), and dihydro-orotase (EC 3.5.2.3)] genes which
occurs in hamster cells resistant to N-(phosphonacetyl)-L-as-
partate, a transition state inhibitor of aspartate transcarbamoyl-
ase (1). CAD, a multifunctional enzyme, catalyzes the first three
reactions of de novo UMP biosynthesis. Relative incidence of
resistant cells and other features of the phenomenon (1) are
strikingly similar to those of the DHFR gene amplification (13,
22).
One can conclude that misfirings of eukaryotic replicons oc-
cur with detectable frequencies and, furthermore, that the sizes
of duplicated elements can vary from those smaller than SV40
DNA (5.2 kb) (2, 10-12) to structures containing several chro-
mosomal domains (100-1000 kb) (23, 27). At least some of the
extra copies of chromosomal domains produced by infrequent
acts of replicon misfiring (Fig. 1A) are converted into extra-
chromosomal chromatin fragments, either by a general recom-
binational enzymatic system or by a special repair-type mech-
anism. The existence of such an excision mechanism is strongly
suggested by recent data on the formation ofcircular SV40 DNA
molecules as a result ofreplication ofSV40 DNA integrated into
the mouse genome in SV40-transformed mouse cells (2) (see
above).
Firone hypothesis
The central idea of the present work is that a low probability
of a replicon misfiring within any given chromosomal domain
(Fig. LA) could be increased by certain substances of either in-
tra- or extracellular origin. The term "firone" is proposed for
such a substance. Firones, as shown below, are expected to in-
fluence strongly the rate of evolution of cellular systems under
a selection pressure, a developing tumor being one example of
such a system. The firone hypothesis leads to several testable
predictions and to a new type of gene dosage assay.
Firones as tumor promoters
Tumor promoters are substances that increase the probability
ofa malignant transformation "initiated" by a previous exposure
of cells to a carcinogen; by definition, tumor promoters have
either very low or no carcinogenic activity when tested in the
absence of an initiating carcinogen (28-41). They comprise a
large variety of substances ofwhich some are weak carcinogens
by themselves and the others display neither carcinogenic nor
detectable mutagenic activity when tested alone in bacterial or
mammalian mutation assays (42-44). Some of the phorbol es-
ters-in particular, 12-O-tetradecanoylphorbol 13-acetate
(TPA)-are extremely potent tumor promoters in the mouse
skin model (28, 29). TPA was also shown recently to increase
the efficiency ofcarcinogen-, virus-, or radiation-induced trans-
formation of cultured mouse cells (45-47).
In spite ofthe large amount ofexperimental work carried out,
the primary mechanism of tumor promotion is not understood
(28-55). TPA and related compounds have been found to pro-
duce a multitude of cellular effects that include stimulation of
macromolecular metabolism and cell growth (28) and ofvarious
plasma membrane functions such as its phospholipid metabo-
lism (28) and sugar transport (51), induction of enzymes such
as plasminogen activator (33) and ornithine decarboxylase (52),
either suppression or enhancement of terminal differentiation
(41), induction of viral antigens (53), and alteration of cellular
structure or shape (51). None of these effects immediately sug-
gests molecular mechanisms for a heritable phenotypic change.
Although epigenetic explanations ofthe tumor promotion effect
(i.e., explanations that do not depend on changes ofeither DNA
sequences or their relative abundances) are not precluded by
the current data, difficulties with these explanations (56) compel
one to look for a genetic mechanism of tumor promotion. One
suggestion was that the promoter facilitates segregation of a re-
cessive chromosomal lesion (transforming gene) through mitotic
recombination (54). However, recent carefully executed at-
tempts failed to confirm an effect of TPA on mitotic recombi-
nation (44, 55).
On the other hand, as shown below, one does not need to
invoke mitotic recombination to achieve at least a partial seg-
regation ofa recessive transforming gene. Induction ofreplicon
misfiring by a firone would lead to more frequent formation of
extra copies of both a transforming gene and its dominant nor-
mal allele (Fig. 1B). These extra copies, in the form of small
acentric chromosomes (DMs) or smaller chromatin fragments,
would be distributed at random at each mitosis. As a result,
some cells would acquire higher-than-average doses of the
transforming gene. This would create conditions for expression
of an initial transformed phenotype, assuming that the normal
allele of a transforming gene is not of an overdominant type.
Growth advantage ofcells with increased doses ofa transforming
gene would lead to preferential retention ofthese cells in a pop-
ulation and to further evolution in the direction ofa transformed
phenotype. Reintegration of acentric chromosomal fragments
carrying a transforming gene into one of the chromosomes
would lead to formation of a stable lineage of transformed cells.
In summary, I suggest that locus-unspecific firones able to
increase incidence ofotherwise rare events ofreplicon misfiring
should act as tumor promoters by facilitating segregation of a
recessive transforming gene. The reverse suggestion, that all
tumor promoters are firones, does not have to be true because
there may be more than one primary mechanism of tumor
promotion.
Firone hypothesis and emergence of malignant phenotypes
in mammalian cell lineages
Evolution of tumor cell populations in vivo toward more ma-
lignant phenotypes is a well-known phenomenon (47, 56-60).
In a developing tumor, those cells that have acquired a direct
and heritable growth advantage-e.g., a shorter generation
time-or a loss of dependence on a particular growth factor in
short supply or an ability to secrete a factor promoting vascu-
larization (61) will eventually outgrow their neighbors and give
rise to a more actively expanding tumor.
A conspicuous feature of tumor cells is their frequent asso-
ciation with small DMs (62-65). DMs are rarely present in nor-
mal mammalian cells but are found frequently and in large num-
bers in naturally occurring malignant tumors (62-65). DMs are
also found in certain types of drug-resistant cells created either
in the laboratory (23) (see above) or in the course of cancer
chemotherapy (16). DMs gradually disappear from tumor cells
under nonselective conditions of in vitro growth but reappear
upon reimplantation of the cells in a susceptible animal (62-64).
This suggests that the presence of DMs, and possibly also of
smaller chromatin fragments undetectable by conventional cy-
tological methods, is of benefit to cells under conditions of
exposing them to MTX. If the number of resistant survivors is significantly higher than the controls, the number of the DHFR genes per MTX-
resistant cell is measured (13, 26), in order to verify that MTX resistance is due to an amplification of the DHFR gene rather than, for instance,
to a mutation rendering DHFR less sensitive to inhibition by MTX. To minimize the possibility that firone activity of a tested substance is due to
a specific disturbance of cellular metabolism caused by MTX, other single-step gene dosage assays of the same type but with different drugs-e.g.,
N-(phosphonacetyl)-L-aspartate (1-can be used. Additional controls, in particular those measuring plating efficiencies in the presence and absence
of a firone, would be also required for a gene dosage assay.
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growth in vivo but not under conditions of growth in a cell cul-
ture. One explanation is that the presence of DMs disturbs a
normal genotypic balance for the corresponding genes, thereby
creating possibilities for phenotypic changes favorable for tumor
cell multiplication and selection.
I suggest that firones of either extracellular or intracellular
origin should influence the rates of tumor cell evolution by in-
creasing the rate of formation of DMs through replicon
misfiring.
The idea that changes in relative dosages of specific genes
may lead to phenotypic changes is by no means new (reviewed
in ref. 56). It is also known that a transcriptional activation of
a transforming gene resulting in overproduction of certain pro-
teins is one ofthe mechanisms ofcellular transformation by RNA
tumor viruses (reviewed in ref. 66). The idea ofthe present work
is that the rate of gene amplification through replicon misfiring
is specifically controlled by firones and that this mechanism
could underlie the observed rapid cellular evolution in devel-
oping tumors and the action of at least some tumor promoters.
In considering the action of firones on cells it is important to
distinguish between firones of extracellular origin and firones
produced within a target cell. In the latter case the rate of cel-
lular evolution becomes no longer dependent on a continuous
supply of an extracellular firone and, in addition, a new evo-
lutionary avenue is created, favoring overproduction of a firone
by the cell. Thus, a chance emergence of a producer of an in-
tracellular firone could set in progress an "autocatalytic" process
in which an increase of firone activity facilitates evolution to-
ward an even more efficient firone producer.
It should be noted that the postulated misfiring produced by
firones would put an extra metabolic burden on both replication
and repair systems and therefore would not be advantageous
for a cell in the absence of a specific selection pressure.
Finally, because evolution of cellular phenotypes through
replicon misfiring is certainly not the only existing evolutionary
avenue, by selectively increasing the rate of misfiring-depen-
dent evolution, firones would change the relative contributions
of different evolutionary mechanisms to an overall process of
heritable phenotypic change in a cellular population.
One of the testable predictions of the firone hypothesis as
applied to evolution of malignant phenotypes is that tumor cells
containing large amounts of DMs or smaller chromatin frag-
ments should contain larger than normal amounts of an intra-
cellular firone. Furthermore, ifsuch a firone should be secreted
from the cell, and be able to act on normal cells, it might be
detected by exposing normal cells to a medium conditioned by
the tumor cells and assaying the normal cells for replicon mis-
firing (see below).
Definition and classification of firones
Although identities of postulated locus-unspecific firones are
unknown, substances that function as a locus-specific firone cer-
tainly exist. For example, an unidentified factor responsible for
a formation of DNA puffs in Rynchosciara (4) clearly satisfies
the definition of a locus-specific firone. Another example of a
locus-specific firone is a combination of a SV40 large tumor an-
tigen and a hitherto unidentified permissive factor for SV40
DNA replication. Both substances are apparently required for
the burst of SV40 replicon misfiring that follows fusion of SV40-
transformed nonpermissive mouse cell with a permissive green
monkey cell (2).
Locus-specific firones are likely to be proteins that recognize
and bind to specific DNA sequences. One possible origin of a
partially or completely locus-unspecific firone would be through
a mutation that diminishes the nucleotide sequence specificity
of a locus-specific firone without destroying its firone activity.
More generally, any substance that increases probability ofrep-
licon misfiring either directly (for example, by binding to a chro-
matin structure involved in suppression of misfiring) or indi-
rectly (for example, by specifically disturbing metabolism oflow
molecular weight compounds important for a proper function-
ing ofthe replication machinery) would be classified as a firone.
Experimental approaches to firone detection
The most straightforward approach to firone detection would
be a biochemical one. That is, one should be able to measure
directly the frequency ofreplicon misfiring in several randomly
chosen regions of the genome in the presence and absence of
a putative firone. Such an assay appears feasible but would re-
quire a technique for detecting and fractionating DNA frag-
ments intermediate in length between chromosome-sized
DNAs (>104 kbp) and the largest DNAs resolvable in conven-
tional agarose gels (-- 102 kbp).
Another way to detect firones would be to use a new type of
gene dosage assay described in the legend to Fig. 1C. The assay
is based on the fact that most cases of resistance of mammalian
cells to MTX are due to the acquisition of extra copies ofDHFR
genes (13). The incidence of cells resistant to given MTX con-
centrations can be measured in a single-step colony formation
assay. In this assay, control cell populations are not treated with
a putative firone. Experimental cells are allowed to grow for a
few generations in the presence of the firone and are subjected
then to single-step selections for resistance to a range of MTX
concentrations. If the frequency of resistant cells is found to be
increased, a set of additional control experiments is carried out
to verify that the resistant phenotype is due to DHFR gene
amplification.
The major point of this work is that the existence of partially
or completely locus-unspecific firones would have important
biological implications.
Note Added in Proof. Recent experiments of the type proposed in Fig.
1C have led to discovery of a dramatic effect of TPA on the incidence
of mouse cells heritably resistant to MTX. These resistant cells have
increased dosages of the DHFR gene (67).
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